In addition, Yoshikawa et al. found Cpd22 (Figure 14A), an oral cerebral transbenzozozoapine RIPK1 kinase inhibitor with good pharmacokinetic activity, significantly inhibited programmed necrosis in human colon cancer cells HT-29 [IC50 (HT-29) = 2.0 nM] and mouse fibroblasts L929 [IC50 (L929) = 15 nM] in response to the low brain tissue distribution of the inhibitor GSK298277259 (Yoshikawa et al., 2018). The gene discussed is RIPK1; the disease is malignant colon neoplasm.